Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets open firm
Tue, 24 Jul 09:30 am

Asian stock markets have opened the day on a mixed note with stock markets in Taiwan (down 0.8%), Japan (down 0.4%) and South Korea (down 0.3%) leading the losses in the region. However, markets in Singapore (up 0.5%) and Indonesia (up 0.3%) are trading firm. The Indian share market indices have opened the day on a firm note. Stocks in the FMCG, capital goods and realty space are leading the pack of gainers.

The Sensex today is up by around 56 points (0.3%), while the NSE-Nifty is up by around 15 points (0.3%). Mid and small cap stocks are also trading in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.5% and 0.4% respectively. The rupee is trading at Rs 56.01 to the US dollar.

Indian pharma stocks have opened the day on a firm note with Torrent Pharma and Orchid Chemicals leading the gains. As per a leading financial daily, Indian pharma firm Lupin is planning to challenge the order of a court in the US state of Delaware that prevents it from selling a low-cost generic version of Pfizer's nerve pain drug pregablin for six years. Last week, the court had allowed Pfizer to retain the marketing monopoly of its two patents for pregablin until December 2018. The order threatens to disrupt Lupin's plan to enter the rapidly growing market of pregabalin in the US. Lyrica, the brand under which Pfizer sells pregablin, accounted for sales worth US$ 1.8 bn in the financial year 2011-12 in the US. Had Pfizer lost this case, Lupin would have got permission to start marketing its drug by October 2013.

Engineering stocks have opened the day on a firm note with Crompton Greaves, Welspun Corporation and Voltas trading firm. Crompton Greaves has announced its financial results for quarter ended June 2012 (1QFY13). During the quarter, consolidated sales grew by 15.3% year-on-year (YoY) to Rs 28,111 m. The growth in the topline was led by power systems segment and consumer products segment, both of which grew by 16.2% YoY and 19.9% YoY, respectively. Operating margins contracted from 7.5% in 1QFY12 to 5.9% in 1QFY13 on account of increase in staff costs and purchase of stock-in-trade. While other income grew by 26.8% YoY during the period, interest expenses and depreciation charges declined by 9.7% and 23.3% YoY, respectively. At the bottomline level, profits increased by 8.1% YoY to Rs 859 m. Net profit margin declined marginally from 3.3% in 1QFY12 to 3.1% in 1QFY13.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.